Loading
Food and Beverage
9 min read
Areas of Expertise :
Food Safety, Epidemiology, Physician, Food Processing
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Northern District of Georgia
Court:
After federal health agencies linked Salmonella Tennessee illnesses to Peter Pan and Great Value peanut butter made at ConAgra’s Sylvester, Georgia plant, ConAgra recalled affected products on February 14, 2007. The resulting lawsuits were centralized in the Northern District of Georgia as MDL No. 1845 for coordinated pretrial proceedings. The litigation involved personal injury and economic-loss claims tied to recalled peanut butter bearing product codes beginning with “2111,” and the court addressed disputes over class certification, causation, product identification, medical proof, and choice of law. In different rulings, the court denied summary judgment where plaintiffs produced evidence that could support causation, but it also granted summary judgment against certain plaintiffs who could not identify the product code or lacked testing and other proof connecting their illnesses to the recalled peanut butter.
The MDL also addressed later-filed individual claims, including a Texas minor’s suit in which the court granted in part and denied in part a motion to dismiss, while a separate federal enforcement case ended with ConAgra Grocery Products LLC entering a guilty plea and paying an $8 million fine plus $3.2 million in forfeiture based on shipments of contaminated peanut butter during the 2006–2007 outbreak. Taken together, the rulings show how the litigation turned on concrete questions of product tracing, laboratory testing, recall scope, and procedural management in a large food safety matter arising from a nationwide Salmonella outbreak.
Federal health agencies warned consumers not to eat certain jars of Peter Pan and Great Value peanut butter after linking the products to Salmonella Tennessee, and ConAgra recalled the affected peanut butter produced at its Sylvester, Georgia plant. Court records later described the recalled jars as bearing product codes beginning with “2111.” That recall set the litigation in motion and placed contamination tracing, product identification, and outbreak-related illness at the center of a major food safety dispute.
As related suits were filed in multiple jurisdictions, the litigation was centralized in the Northern District of Georgia as In re ConAgra Peanut Butter Products Liability Litigation, MDL No. 1845, for coordinated pretrial proceedings. The centralized docket gathered personal injury and related claims arising from the same recall and alleged contamination event. This procedural step moved the matter from scattered filings into a single court-led process focused on shared factual and legal questions.
In one member case, the court denied ConAgra’s motion for summary judgment against Patricia Ladd, who alleged that recalled Great Value peanut butter caused her illness. The order discussed affidavit testimony from Dr. Ben Garza, Ladd’s treating physician, about the testing performed, the limits of the initial stool culture, the persistence of symptoms after treatment for ascariasis, and his medical conclusion on causation. The ruling showed that a claim supported by product-specific facts and treating-physician evidence could continue within the MDL.
In another group of consolidated personal injury actions, the court granted summary judgment against certain plaintiffs who could not identify a relevant product code or did not have testing or other proof connecting their illnesses to the recalled peanut butter. Other claims remained in the litigation where the evidentiary record was stronger. This stage moved the case forward by separating claims with sufficient causation support from claims the court found too weak to proceed.
In a later personal injury action brought on behalf of Taylor Elander, the court granted in part and denied in part ConAgra’s partial motion to dismiss. The ruling allowed core claims tied to the recalled peanut butter to continue while removing some claims and dismissing the mother’s individual claims. It also showed that the MDL still involved active disputes over pleading standards, applicable law, and the scope of recoverable relief years after the recall.
By 2015, the multidistrict litigation had run through years of coordinated pretrial proceedings involving class issues, causation disputes, product tracing, and the sufficiency of proof in individual actions. The federal MDL docket reflects that the civil proceeding closed that year after the litigation that grew out of the 2007 recall had moved through its coordinated pretrial stages. This is the clearest supported point at which the civil ConAgra peanut butter litigation can be described as having ended in federal court.
In a separate federal matter, the United States filed an Information against ConAgra Grocery Products LLC alleging shipment of contaminated peanut butter into interstate commerce in 2006. The filing described the same 2006–2007 outbreak that had already led to the recall and civil litigation, including reported illnesses tied to the contaminated products. This proceeding was distinct from the MDL, but it arose from the same contamination event and extended the broader legal story beyond the civil case closure.
ConAgra Grocery Products LLC pleaded guilty to a misdemeanor Food, Drug, and Cosmetic Act charge, and the court imposed an $8 million fine plus $3.2 million in forfeiture. The government also stated that restitution was not authorized in that matter. With that outcome, the separate federal case reached its final resolution, closing the last major court chapter tied to the peanut butter contamination event.
United States District Court for the Northern District of Georgia
Case Name:
In re ConAgra Peanut Butter Products Liability Litigation
Salmonella
Foodborne Illness
Food microbiology
Food Poisoning
Contamination
Laboratory Testing
Product Recalls
Causation Analysis
After federal health agencies linked Salmonella Tennessee illnesses to Peter Pan and Great Value peanut butter made at ConAgra’s Sylvester, Georgia plant, ConAgra recalled affected products on February 14, 2007. The resulting lawsuits were centralized in the Northern District of Georgia as MDL No. 1845 for coordinated pretrial proceedings. The litigation involved personal injury and economic-loss claims tied to recalled peanut butter bearing product codes beginning with “2111,” and the court addressed disputes over class certification, causation, product identification, medical proof, and choice of law. In different rulings, the court denied summary judgment where plaintiffs produced evidence that could support causation, but it also granted summary judgment against certain plaintiffs who could not identify the product code or lacked testing and other proof connecting their illnesses to the recalled peanut butter.
The MDL also addressed later-filed individual claims, including a Texas minor’s suit in which the court granted in part and denied in part a motion to dismiss, while a separate federal enforcement case ended with ConAgra Grocery Products LLC entering a guilty plea and paying an $8 million fine plus $3.2 million in forfeiture based on shipments of contaminated peanut butter during the 2006–2007 outbreak. Taken together, the rulings show how the litigation turned on concrete questions of product tracing, laboratory testing, recall scope, and procedural management in a large food safety matter arising from a nationwide Salmonella outbreak.
Federal health agencies warned consumers not to eat certain jars of Peter Pan and Great Value peanut butter after linking the products to Salmonella Tennessee, and ConAgra recalled the affected peanut butter produced at its Sylvester, Georgia plant. Court records later described the recalled jars as bearing product codes beginning with “2111.” That recall set the litigation in motion and placed contamination tracing, product identification, and outbreak-related illness at the center of a major food safety dispute.
As related suits were filed in multiple jurisdictions, the litigation was centralized in the Northern District of Georgia as In re ConAgra Peanut Butter Products Liability Litigation, MDL No. 1845, for coordinated pretrial proceedings. The centralized docket gathered personal injury and related claims arising from the same recall and alleged contamination event. This procedural step moved the matter from scattered filings into a single court-led process focused on shared factual and legal questions.
In one member case, the court denied ConAgra’s motion for summary judgment against Patricia Ladd, who alleged that recalled Great Value peanut butter caused her illness. The order discussed affidavit testimony from Dr. Ben Garza, Ladd’s treating physician, about the testing performed, the limits of the initial stool culture, the persistence of symptoms after treatment for ascariasis, and his medical conclusion on causation. The ruling showed that a claim supported by product-specific facts and treating-physician evidence could continue within the MDL.
In another group of consolidated personal injury actions, the court granted summary judgment against certain plaintiffs who could not identify a relevant product code or did not have testing or other proof connecting their illnesses to the recalled peanut butter. Other claims remained in the litigation where the evidentiary record was stronger. This stage moved the case forward by separating claims with sufficient causation support from claims the court found too weak to proceed.
In a later personal injury action brought on behalf of Taylor Elander, the court granted in part and denied in part ConAgra’s partial motion to dismiss. The ruling allowed core claims tied to the recalled peanut butter to continue while removing some claims and dismissing the mother’s individual claims. It also showed that the MDL still involved active disputes over pleading standards, applicable law, and the scope of recoverable relief years after the recall.
By 2015, the multidistrict litigation had run through years of coordinated pretrial proceedings involving class issues, causation disputes, product tracing, and the sufficiency of proof in individual actions. The federal MDL docket reflects that the civil proceeding closed that year after the litigation that grew out of the 2007 recall had moved through its coordinated pretrial stages. This is the clearest supported point at which the civil ConAgra peanut butter litigation can be described as having ended in federal court.
In a separate federal matter, the United States filed an Information against ConAgra Grocery Products LLC alleging shipment of contaminated peanut butter into interstate commerce in 2006. The filing described the same 2006–2007 outbreak that had already led to the recall and civil litigation, including reported illnesses tied to the contaminated products. This proceeding was distinct from the MDL, but it arose from the same contamination event and extended the broader legal story beyond the civil case closure.
ConAgra Grocery Products LLC pleaded guilty to a misdemeanor Food, Drug, and Cosmetic Act charge, and the court imposed an $8 million fine plus $3.2 million in forfeiture. The government also stated that restitution was not authorized in that matter. With that outcome, the separate federal case reached its final resolution, closing the last major court chapter tied to the peanut butter contamination event.
1. Treating Physician Expert Witness (Plaintiff)
Dr. Ben Garza is the clearest publicly identified medical witness in the reviewed record. In the Patricia Ladd order, the court discussed his affidavit testimony about the testing performed, the limits of the initial stool culture, the persistence of symptoms after treatment for ascariasis, and his medical conclusion on causation. Because those points are directly described in the court order, he can be included safely without overstating his role.
2. Food Safety Expert Witness
A food safety expert is often engaged in contaminated-food litigation involving recalls, plant conditions, and regulatory compliance issues. In a case like this, that expert would commonly review sanitation practices, contamination-prevention measures, recall scope, and whether food-production controls aligned with applicable safety requirements.
3. Food Microbiology Expert Witness
A food microbiology expert is often engaged when a case turns on contamination pathways, pathogen presence, and laboratory interpretation. In this type of matter, that expert would commonly assess how salmonella may enter a production environment, persist in a product, and be detected through testing.
4. Epidemiology Expert Witness
An epidemiology expert is often engaged to evaluate outbreak patterns, exposure links, and the relationship between a product and reported illnesses across a population. In litigation like this, that expert would commonly review case clustering, timing, and agency outbreak findings.
1. Build Causation Early With Product-Specific Proof
The ConAgra rulings show that causation turned heavily on whether a plaintiff could connect an illness to the recalled peanut butter through product codes, timing, and medical records. Attorneys handling food safety cases should secure purchase details, packaging information, recall identifiers, and treatment records as early as possible. Weak product tracing can narrow or end a claim before trial.
2. Treat Medical Testing Gaps With Precision, Not Assumptions
The record shows that the court closely examined whether testing actually addressed salmonella and whether other conditions could explain the reported symptoms. Where laboratory proof is incomplete, counsel should develop a careful factual record through treating physicians and contemporaneous medical evidence rather than relying on broad conclusions. That approach can matter in recall-related food safety litigation where symptoms overlap with other gastrointestinal illnesses.
3. Use MDL Procedure to Separate Shared Issues From Individual Proof
This litigation moved forward through coordinated pretrial treatment of common issues, while still leaving plaintiff-specific causation and damages questions to individual proof. For attorneys, the key lesson is to distinguish between case-wide issues such as recall scope and contamination background, and individualized issues such as exposure, illness, and medical causation. Clear issue separation helps keep the case organized and improves motion practice.
4. Challenge or Defend Claims Through Traceability and Record Quality
The court’s rulings show that claims with stronger product identification and medical support were positioned differently from claims lacking those details. Defense counsel can focus on missing product codes, limited testing, and alternate explanations for illness, while plaintiffs’ counsel must close those gaps with disciplined fact development. In a food safety recall case, record quality often drives the outcome as much as the broader contamination event.
5. Keep Civil Resolution and Federal Enforcement History Distinct
The overall ConAgra matter involved both the civil MDL and a separate federal enforcement case arising from the same contaminated peanut butter event. Attorneys should present those tracks clearly and avoid blending the MDL’s civil rulings with the later enforcement outcome. That distinction improves accuracy, keeps the procedural story clear, and helps readers understand the full litigation path without confusion.
The ConAgra peanut butter litigation arose from the 2007 recall of Peter Pan and Great Value peanut butter linked to Salmonella Tennessee and developed into a federal MDL centered on product identification, causation, medical proof, and the limits of claims that could not be tied closely enough to the recalled jars. The court’s rulings allowed some claims to continue where the record included product-specific facts and supporting medical evidence, while narrowing other claims where proof of exposure or causation was too limited. The matter later closed on two separate tracks: the civil MDL closed in federal court, and a separate federal enforcement case ended with a guilty plea, an $8 million fine, and $3.2 million in forfeiture. Taken together, the case shows how recall litigation and food safety disputes can turn on traceability, testing, and the quality of proof connecting a claimed illness to a recalled product.
What was the ConAgra peanut butter litigation about?
The litigation arose after Peter Pan and Great Value peanut butter made at ConAgra’s Sylvester, Georgia plant were linked to a Salmonella Tennessee outbreak and recalled in February 2007. Consumers then brought lawsuits alleging illness and related losses tied to the recalled products. The cases were later handled together in a federal multidistrict proceeding.
What products were involved in the recall?
The recall involved certain jars of Peter Pan and Great Value peanut butter tied to the Sylvester plant. Court records described the affected jars as bearing product codes beginning with “2111.” Product identification became a central issue because the litigation often turned on whether a plaintiff could connect a claimed illness to the recalled peanut butter.
Why was the ConAgra case handled as an MDL?
The lawsuits were centralized in the Northern District of Georgia as MDL No. 1845 so related cases from different jurisdictions could move through coordinated pretrial proceedings. That process allowed the court to address shared issues such as contamination background, recall facts, causation disputes, and pleading challenges in a more organized way. It did not remove the need for plaintiff-specific proof in individual claims.
What legal issues mattered most in the case?
The most important issues included causation, product tracing, medical proof, and whether a plaintiff could tie an illness to the recalled peanut butter rather than another source. The court also addressed class-related questions, motions to dismiss, summary judgment requests, and choice-of-law disputes in later-filed cases. In practical terms, the case turned on how well each claim was supported by records, testing, and recall-specific facts.
How did food safety issues affect the outcome of the litigation?
1. Treating Physician Expert Witness (Plaintiff)
Dr. Ben Garza is the clearest publicly identified medical witness in the reviewed record. In the Patricia Ladd order, the court discussed his affidavit testimony about the testing performed, the limits of the initial stool culture, the persistence of symptoms after treatment for ascariasis, and his medical conclusion on causation. Because those points are directly described in the court order, he can be included safely without overstating his role.
2. Food Safety Expert Witness
A food safety expert is often engaged in contaminated-food litigation involving recalls, plant conditions, and regulatory compliance issues. In a case like this, that expert would commonly review sanitation practices, contamination-prevention measures, recall scope, and whether food-production controls aligned with applicable safety requirements.
3. Food Microbiology Expert Witness
A food microbiology expert is often engaged when a case turns on contamination pathways, pathogen presence, and laboratory interpretation. In this type of matter, that expert would commonly assess how salmonella may enter a production environment, persist in a product, and be detected through testing.
4. Epidemiology Expert Witness
An epidemiology expert is often engaged to evaluate outbreak patterns, exposure links, and the relationship between a product and reported illnesses across a population. In litigation like this, that expert would commonly review case clustering, timing, and agency outbreak findings.
1. Build Causation Early With Product-Specific Proof
The ConAgra rulings show that causation turned heavily on whether a plaintiff could connect an illness to the recalled peanut butter through product codes, timing, and medical records. Attorneys handling food safety cases should secure purchase details, packaging information, recall identifiers, and treatment records as early as possible. Weak product tracing can narrow or end a claim before trial.
2. Treat Medical Testing Gaps With Precision, Not Assumptions
The record shows that the court closely examined whether testing actually addressed salmonella and whether other conditions could explain the reported symptoms. Where laboratory proof is incomplete, counsel should develop a careful factual record through treating physicians and contemporaneous medical evidence rather than relying on broad conclusions. That approach can matter in recall-related food safety litigation where symptoms overlap with other gastrointestinal illnesses.
3. Use MDL Procedure to Separate Shared Issues From Individual Proof
This litigation moved forward through coordinated pretrial treatment of common issues, while still leaving plaintiff-specific causation and damages questions to individual proof. For attorneys, the key lesson is to distinguish between case-wide issues such as recall scope and contamination background, and individualized issues such as exposure, illness, and medical causation. Clear issue separation helps keep the case organized and improves motion practice.
4. Challenge or Defend Claims Through Traceability and Record Quality
The court’s rulings show that claims with stronger product identification and medical support were positioned differently from claims lacking those details. Defense counsel can focus on missing product codes, limited testing, and alternate explanations for illness, while plaintiffs’ counsel must close those gaps with disciplined fact development. In a food safety recall case, record quality often drives the outcome as much as the broader contamination event.
5. Keep Civil Resolution and Federal Enforcement History Distinct
The overall ConAgra matter involved both the civil MDL and a separate federal enforcement case arising from the same contaminated peanut butter event. Attorneys should present those tracks clearly and avoid blending the MDL’s civil rulings with the later enforcement outcome. That distinction improves accuracy, keeps the procedural story clear, and helps readers understand the full litigation path without confusion.
The ConAgra peanut butter litigation arose from the 2007 recall of Peter Pan and Great Value peanut butter linked to Salmonella Tennessee and developed into a federal MDL centered on product identification, causation, medical proof, and the limits of claims that could not be tied closely enough to the recalled jars. The court’s rulings allowed some claims to continue where the record included product-specific facts and supporting medical evidence, while narrowing other claims where proof of exposure or causation was too limited. The matter later closed on two separate tracks: the civil MDL closed in federal court, and a separate federal enforcement case ended with a guilty plea, an $8 million fine, and $3.2 million in forfeiture. Taken together, the case shows how recall litigation and food safety disputes can turn on traceability, testing, and the quality of proof connecting a claimed illness to a recalled product.
What was the ConAgra peanut butter litigation about?
The litigation arose after Peter Pan and Great Value peanut butter made at ConAgra’s Sylvester, Georgia plant were linked to a Salmonella Tennessee outbreak and recalled in February 2007. Consumers then brought lawsuits alleging illness and related losses tied to the recalled products. The cases were later handled together in a federal multidistrict proceeding.
What products were involved in the recall?
The recall involved certain jars of Peter Pan and Great Value peanut butter tied to the Sylvester plant. Court records described the affected jars as bearing product codes beginning with “2111.” Product identification became a central issue because the litigation often turned on whether a plaintiff could connect a claimed illness to the recalled peanut butter.
Why was the ConAgra case handled as an MDL?
The lawsuits were centralized in the Northern District of Georgia as MDL No. 1845 so related cases from different jurisdictions could move through coordinated pretrial proceedings. That process allowed the court to address shared issues such as contamination background, recall facts, causation disputes, and pleading challenges in a more organized way. It did not remove the need for plaintiff-specific proof in individual claims.
What legal issues mattered most in the case?
The most important issues included causation, product tracing, medical proof, and whether a plaintiff could tie an illness to the recalled peanut butter rather than another source. The court also addressed class-related questions, motions to dismiss, summary judgment requests, and choice-of-law disputes in later-filed cases. In practical terms, the case turned on how well each claim was supported by records, testing, and recall-specific facts.
How did food safety issues affect the outcome of the litigation?
Food safety issues were central because the case grew out of a nationwide Salmonella outbreak, a recall, and claims involving contaminated food products. The litigation repeatedly focused on contamination tracing, recall scope, product codes, and the reliability of medical and laboratory proof. Those facts made the case a clear example of how outbreak-related lawsuits depend on careful proof of exposure and illness.
How did the ConAgra peanut butter litigation end?
The civil multidistrict litigation reached its endpoint in federal court in 2015 after years of coordinated proceedings. Separately, a federal enforcement case tied to the same contaminated peanut butter event ended in 2016 with a guilty plea, an $8 million fine, and $3.2 million in forfeiture. Together, those outcomes closed the main court proceedings arising from the recall and outbreak.
Salmonella
Foodborne Illness
Food microbiology
Food Poisoning
Contamination
Laboratory Testing
Product Recalls
Causation Analysis
Wage And Hour Disputes, +4
Food and Beverage
Food And Beverage, +4
Food and Beverage
Food safety issues were central because the case grew out of a nationwide Salmonella outbreak, a recall, and claims involving contaminated food products. The litigation repeatedly focused on contamination tracing, recall scope, product codes, and the reliability of medical and laboratory proof. Those facts made the case a clear example of how outbreak-related lawsuits depend on careful proof of exposure and illness.
How did the ConAgra peanut butter litigation end?
The civil multidistrict litigation reached its endpoint in federal court in 2015 after years of coordinated proceedings. Separately, a federal enforcement case tied to the same contaminated peanut butter event ended in 2016 with a guilty plea, an $8 million fine, and $3.2 million in forfeiture. Together, those outcomes closed the main court proceedings arising from the recall and outbreak.